Almirall SA
ALM
ISIN ES0157097017 / Valor 3180354
Almirall SA
UMushroom community rating:
About company
Almirall SA is a Barcelona-based global pharmaceutical company that focuses on skin health, partnering with healthcare professionals to provide medical solutions for patients. The company's efforts are concentrated on combating skin health diseases and enhancing the well-being of individuals. Almirall has a diverse portfolio of products, including treatments for acne, dermatoses, nail diseases, onychomycosis, nail psoriasis, nail dystrophy, skin mycosis, rosacea, and COPD. Additionally, the company has engaged in strategic acquisitions and partnerships to expand its offerings and reach in the pharmaceutical industry.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (12.10.2025):
In the first half of 2025, Almirall SA reported a robust financial performance with net sales increasing by 12.7% to €560.5 million and EBITDA rising by 16.6% year-over-year to €121.8 million. This growth was primarily driven by the strong performance of the biologics portfolio and the company’s commitment to operational excellence.
Biologics Drive Significant Growth
Ebglyss® achieved impressive net sales of €44.9 million, more than quadrupling year-over-year across 14 European countries. Ilumetri® also showed steady growth with a 12.7% increase in sales, totaling €113.3 million in H1 2025, solidifying its position as a key revenue generator.
European Dermatology Business Flourishes
Almirall maintained its leadership in medical dermatology in Europe, supported by the continued growth of Wynzora® (€17.1 million, up 32.6% YoY) and Klisyri® (€13.7 million, up 25.7% YoY). The broad product portfolio underpins the company’s strong market presence and sustained demand.
Confirmed Full-Year Guidance and Positive Outlook
Almirall reiterated its full-year 2025 guidance, anticipating double-digit net sales growth and EBITDA targets. The positive outlook is supported by the ongoing strong performance of the biologics portfolio and the company’s dedication to operational excellence.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
3079 M
Market cap (USD)
167,866
Daily traded volume (Shares)
8.14 / 8.03
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
